Your browser doesn't support javascript.
loading
Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for BRAF V600-Mutant Unresectable or Metastatic Melanoma.
Dummer, Reinhard; Long, Georgina V; Robert, Caroline; Tawbi, Hussein A; Flaherty, Keith T; Ascierto, Paolo A; Nathan, Paul D; Rutkowski, Piotr; Leonov, Oleg; Dutriaux, Caroline; Mandalà, Mario; Lorigan, Paul; Ferrucci, Pier Francesco; Grob, Jean Jacques; Meyer, Nicolas; Gogas, Helen; Stroyakovskiy, Daniil; Arance, Ana; Brase, Jan C; Green, Steven; Haas, Tomas; Masood, Aisha; Gasal, Eduard; Ribas, Antoni; Schadendorf, Dirk.
Afiliação
  • Dummer R; University Hospital Zürich Skin Cancer Center, Zürich, Switzerland.
  • Long GV; Melanoma Institute Australia, The University of Sydney, and Royal North Shore and Mater Hospitals, Sydney, New South Wales, Australia.
  • Robert C; Gustave Roussy, Villejuif, and Paris-Saclay University, Orsay, France.
  • Tawbi HA; The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Flaherty KT; Dana-Farber Cancer Institute/Harvard Medical School and Massachusetts General Hospital, Boston, MA.
  • Ascierto PA; Istituto Nazionale Tumori, IRCCS, Fondazione "G. Pascale," Naples, Italy.
  • Nathan PD; Mount Vernon Cancer Centre, Northwood, United Kingdom.
  • Rutkowski P; Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.
  • Leonov O; Clinical Oncological Dispensary, Omsk, Russia.
  • Dutriaux C; Centre Hospitalier Universitaire de Bordeaux, Hôpital Saint-André, Bordeaux, France.
  • Mandalà M; Unit of Medical Oncology, University of Perugia, Perugia, Italy.
  • Lorigan P; Unit of Medical Oncology, Papa Giovanni XXIII Cancer Center Hospital, Bergamo, Italy.
  • Ferrucci PF; University of Manchester and The Christie NHS Foundation Trust, Manchester, United Kingdom.
  • Grob JJ; Department of Experimental Oncology, European Institute of Oncology, IRCCS, Milan, Italy.
  • Meyer N; Timone Hospital AP-HM and Aix-Marseille University, Marseille, France.
  • Gogas H; Université Toulouse III-Paul Sabatier, Institut National de la Santé et de la Recherche Médicale Unité Mixte de Recherche 1037-CRCT, Toulouse, France.
  • Stroyakovskiy D; Laiko General Hospital, National and Kapodistrian University of Athens School of Medicine, Athens, Greece.
  • Arance A; Moscow City Oncology Hospital, Moscow, Russia.
  • Brase JC; Hospital Clinic of Barcelona, Barcelona, Spain.
  • Green S; Novartis Pharma AG, Basel, Switzerland.
  • Haas T; Novartis Pharma AG, Basel, Switzerland.
  • Masood A; Novartis Pharma AG, Basel, Switzerland.
  • Gasal E; Novartis Pharmaceuticals Corporation, East Hanover, NJ.
  • Ribas A; Novartis Pharmaceuticals Corporation, East Hanover, NJ.
  • Schadendorf D; Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, CA.
J Clin Oncol ; 40(13): 1428-1438, 2022 05 01.
Article em En | MEDLINE | ID: mdl-35030011
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Cutâneas / Segunda Neoplasia Primária / Melanoma Tipo de estudo: Clinical_trials / Etiology_studies Limite: Adolescent / Adult / Humans Idioma: En Revista: J Clin Oncol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Suíça
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Cutâneas / Segunda Neoplasia Primária / Melanoma Tipo de estudo: Clinical_trials / Etiology_studies Limite: Adolescent / Adult / Humans Idioma: En Revista: J Clin Oncol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Suíça